VERA Vera Therapeutics, Inc. Class A Common Stock
XNAS
30.82
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VERA
$30.82
—
What changed
Recent filings, trades and movesKey stats
$30.82
- 52-Week Range
- $26.00 – $56.05
- YTD
- -36.61%
- IV Rank (30D)
- 35.63
- Straddle Price
- $5.75
- P/C Vol Ratio
- 0.62
- Market Cap
- $2.1B
- Open
- $30.40
- Day Range
- $28.86 – $30.86
- Volume
- 922,035
- Prev Close
- $29.79
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.87 |
| Cost of Equity (CAPM) | 9.25% (VRP-adj) |
| WACC | 9.16% |
| Volatility Risk Premium | +36.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.3B |
| Return on Equity (TTM) | -98.9% |
| Book / Price | 19.1% |
| Debt / Equity | 0.18 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $31.60 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $29.43 |
| Bollinger Width / SMA20 | 20.0% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $2B |
Peers used for multiples: APGE, CGON, CRNX, DNTH, DYN, ORKA, TVTX, XENE
60-Day Conviction
68%
20-Day Fair Value
≈ by Dec 8, 2026
$30.78
α +0.0%
rank 40%
conviction
1%
40-Day Fair Value
≈ by Jan 6, 2027
$32.15
α +4.5%
rank 48%
conviction
94%
60-Day Fair Value
≈ by Feb 4, 2027
$31.70
α +3.0%
rank 43%
conviction
68%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $32.01 | 21% | median 5.6× · 8 peers |
| Peer P/S | n/a | 0% | median 568.0× · 4 peers |
| Market Anchor (SMA50) | $31.60 | 53% | stability 50% (BB-width) |
| Options Expected (B-L 30d) | $30.37 | 26% | 10 strikes · skew -0.01 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $2.1B
- Employees
- 362
- List Date
- 2021-05-14
- CIK
- 0001831828
- Last Earnings
- Nov 5 after close · −1.2% vs ±15.3% expected
- Next Earnings
- ~Feb 25, 2027 (estimated)
- Headquarters
- Brisbane, CA
- Homepage
- https://www.veratx.com
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -28.97% | -53.66% | 133.31% | -11.66% | -11.02% | 5.60% |
| Feb | -- | 15.42% | -12.49% | 23.89% | -18.09% | -9.92% | -0.24% |
| Mar | -- | 2.67% | 4.86% | -12.25% | -15.45% | -0.47% | -4.13% |
| Apr | -- | -12.51% | -12.04% | -6.71% | 6.13% | -12.07% | -7.44% |
| May | 50.00% | -27.81% | 20.14% | -10.23% | -20.21% | 0.91% | 2.13% |
| Jun | -14.73% | -2.92% | 79.33% | -10.16% | -25.77% | 26.43% | 8.70% |
| Jul | 31.29% | 29.99% | 18.12% | 0.83% | -9.61% | -24.60% | 7.67% |
| Aug | -15.29% | 27.67% | -7.29% | 0.53% | 3.29% | 5.74% | 2.44% |
| Sep | 7.50% | -0.42% | -26.05% | 15.22% | 28.53% | -5.67% | 3.19% |
| Oct | 6.44% | -8.67% | -19.54% | -5.72% | -1.15% | -0.03% | -4.78% |
| Nov | 102.15% | -8.94% | 23.97% | 13.53% | 30.11% | 1.72%* | 27.09% |
| Dec | -19.71% | 18.35% | 11.13% | -14.65% | 53.45% | -- | 9.71% |
| Total | 164.18% | -16.05% | -27.66% | 103.61% | -8.92% | -31.56% | 30.60% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $29.58
SMA 50: $31.53
SMA 200: $36.48
Current: $30.78
EMA 12: $30.31
EMA 26: $30.38
MACD: -0.0698 | Signal: 0.2412
BEARISH
ADX (14): 13.35
RANGE
+DI: 23.81
−DI: 24.02
Momentum Oscillators
RSI (14): 51.54
NEUTRAL
Stoch %K: 52.16
Stoch %D: 59.32
Williams %R: -37.59
Volume & Volatility
BB Upper: $32.46
BB Lower: $26.69
NEUTRAL
OBV: -21,081,997
Vol SMA 20: 1,611,403
Vol ROC: -21.35%
ATR: $1.84
True Range: $2.00
HV 20: 61.2%
HV 30: 57.5%
HV 60: 58.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before VERA’s Nov 5 earnings report, so it doesn’t reflect the results.
Here is my comprehensive stock analysis report for VERA:
Executive Summary
Overall assessment: BEARISH (confidence level 6/10)
Key drivers: High volatility, overbought RSI, potential catalysts in the form of earnings announcements.
Primary risks: High beta, negative news sentiment, technical breakdowns.
Investment thesis: Weighing the benefits of Vera Therapeutics' proposed public offering against the risks associated with its high volatility and overbought conditions. Recent news headlines suggest a focus on financing rather than significant product updates, which could impact the stock's short-term performance.
Recent news sentiment impact: The positive sentiment from the proposed public offering has contributed to the stock's recent gains, but we believe this is a transient effect and that the bearish signals will eventually prevail.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH, Medium-term (1-3 months): NEUTRAL, Long-term (3-12 months): BULLISH
Support/Resistance Levels: Key price levels from moving averages: $30.61 (SMA 50), $32.92 (SMA 20)
Momentum Signals: RSI interpretation: Overbought (>70) MACD signal: Bullish Bollinger Bands position: Squeeze
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 1890404.10
- On-Balance Volume (OBV): 19892014.00
- Volume Rate of Change: 155.96%
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles: Financing, public offering, partnerships.
Sentiment Assessment: Aggregate news sentiment: NEUTRAL
Catalyst Identification: Upcoming earnings announcements, potential regulatory changes.
Market Narrative: How news aligns with or contradicts technical signals: The positive news headlines on the proposed public offering have contributed to the stock's recent gains, but we believe this is a transient effect and that the bearish signals will eventually prevail.
Risk & Volatility Assessment
Beta Interpretation: High beta (1.26), indicating more volatility than the market.
Volatility Regime: Current vs historical volatility levels: Higher than average.
Options Market Signals: IV Rank: 100.0% (High) Current IV: 229.4% Expected Move: $10.38 (39 DTE), 7-DTE: $7.02
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: Above average.
Institutional Activity: Volume patterns suggesting institutional interest signals:
- Volume SMA 20: 1890404.10
- On-Balance Volume (OBV): 19892014.00
- Volume Rate of Change: 155.96%
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Correlation: 0.26
- R-squared: 6.51%
Key Levels & Action Items
Critical Price Levels: Support/resistance levels from moving averages and technical patterns:
- $30.61 (SMA 50)
- $32.92 (SMA 20)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- $44.52 (Upper Bollinger Band)
- $21.31 (Lower Bollinger Band)
Time-Sensitive Catalysts: Earnings announcements, regulatory changes.
Risk Management: Stop-loss levels and position sizing considerations:
- Stop-loss: Below $30.61 (SMA 50) or above $44.52 (Upper Bollinger Band)
- Position sizing: 5-10% of portfolio
Generated
News
All VERA news →
Launch momentum and kidney data stand out, but cash burn is climbing fast.
Earnings History
16 of 16 under expected move
Avg Expected Move
15.94%
Avg Actual Move
4.10%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-08-10 | After-Close | 17.46% | 5.96% | 0.34x | Within |
| 2023-11-09 | After-Close | 26.32% | 5.47% | 0.21x | Within |
| 2024-01-29 | After-Close | 19.47% | 2.59% | 0.13x | Within |
| 2024-03-20 | After-Close | 15.55% | 5.43% | 0.35x | Within |
| 2024-05-09 | After-Close | 9.57% | 2.39% | 0.25x | Within |
| 2024-08-08 | After-Close | 11.58% | 0.36% | 0.03x | Within |
| 2024-10-28 | After-Close | 16.63% | 9.23% | 0.56x | Within |
| 2024-11-07 | Pre-Market | 12.83% | 2.29% | 0.18x | Within |
| 2025-02-26 | After-Close | 20.26% | 5.91% | 0.29x | Within |
| 2025-05-06 | After-Close | 20.10% | 2.77% | 0.14x | Within |
| 2025-08-05 | After-Close | 7.75% | 6.73% | 0.87x | Within |
| 2025-11-05 | After-Close | 25.10% | 4.65% | 0.19x | Within |
| 2026-02-26 | After-Close | 14.70% | 3.68% | 0.25x | Within |
| 2026-05-05 | After-Close | 12.67% | 6.01% | 0.47x | Within |
| 2026-08-11 | After-Close | 9.66% | 0.99% | 0.10x | Within |
| 2026-11-05 | After-Close | 15.35% | 1.18% | 0.08x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VERA Options Activity & IV Rank
VERA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 77.1%
7-DTE IV: 106.0%
Expected Move: $5.75
7-DTE Move: $4.58
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 860
Put Volume: 536
P/C Volume: 0.623
BULLISH
Call OI: 16,845
Put OI: 16,740
P/C OI: 0.994
Total OI: 33,585
ATM Options Pricing
ATM Call: $2.60
ATM Put: $3.15
Call %: 8.4%
Put %: 10.2%
Chain Summary
Chain Volume: 1,396
Chain OI: 33,585
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 22nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
22%
vs own history
GEX tilt
-0.30
OI-weighted, today
Vanna tilt
-0.35
δ-sensitivity to IV
Charm tilt
-0.50
δ-decay vs time
Vanna tilt -0.35: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.50: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 11 ATM contracts, 22k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)46.4MediumNov 9
IV Rank (30 DTE)35.6MediumNov 9
Straddle Price (30 DTE)$5.75Nov 9
Beta Analysis
Risk Metrics
Beta: 1.3585
Alpha: 25.26%
Correlation: 0.3064
R-Squared: 9.4%
Stock Volatility: 61.1%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own VERA
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $12.0M | #956 of 3138 | -38.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $12.0M | #1458 of 3716 | -5.1% | 13F | |
| Point72 Hedge fund Steve Cohen | $1.7M | #1321 of 1945 | -96.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $64K | #3231 of 4729 | -17.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VERA Institutional Ownership (13F)
Filings for 2026-06-30 · 67 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 68,197,249 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$13.25M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.15M | 23.77% | 2026-06-30 |
| 2 | Ikarian Capital, LLC | $3.08M | 23.22% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $2.16M | 16.32% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $1.69M | 12.73% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $1.14M | 8.63% | 2026-09-30 |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | $901.11K | 6.80% | 2026-06-30 |
| 7 | NOMURA HOLDINGS INC | $862.49K | 6.51% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $270.33K | 2.04% | 2026-06-30 |
8 filers$8.10M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.98M | 36.83% | 2026-06-30 |
| 2 | DIADEMA PARTNERS LP | $2.15M | 26.49% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.53M | 18.86% | 2026-06-30 |
| 4 | NOMURA HOLDINGS INC | $858.20K | 10.60% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $463.43K | 5.72% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $60.07K | 0.74% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $32.29K | 0.40% | 2026-09-30 |
| 8 | Persistent Asset Partners Ltd | $28.44K | 0.35% | 2026-06-30 |
VERA Insider Trading (Form 4)
Latest: 2026-09-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Marshall Fordyce | PRESIDENT AND CEO | Mixed Sell −18,500 · Exer +18,500 |
— | $19.95 | -$630.9K | EDGAR |
| 2026-09-14 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | Exer (M) | +5,000 | $3.94 | $19.7K | EDGAR |
| 2026-09-04 | Marshall Fordyce | PRESIDENT AND CEO | Mixed Exer +18,500 · Sell −18,500 |
— | $19.01 | -$596.1K | EDGAR |
| 2026-08-12 | Marshall Fordyce | PRESIDENT AND CEO | Mixed Sell −46,250 · Exer +46,250 |
— | $22.60 | -$1.82M | EDGAR |
| 2026-08-12 | Marshall Fordyce | PRESIDENT AND CEO | Mixed Sell −18,500 · Exer +18,500 |
— | $19.82 | -$626.2K | EDGAR |
| 2026-08-12 | Marshall Fordyce | PRESIDENT AND CEO | Mixed Exer +18,500 · Sell −18,500 |
— | $20.42 | -$648.2K | EDGAR |
| 2026-08-05 | Nancy Lee Boman | Chief Regulatory Officer | Award (A) | +44,987 | — | EDGAR | |
| 2026-07-09 | Marshall Fordyce | PRESIDENT AND CEO | Sell (S) | −46,250 | $42.30 | -$1.96M | EDGAR |
| 2026-06-24 | Marshall Fordyce | PRESIDENT AND CEO | Sell (S) | −18,500 | $37.93 | -$701.8K | EDGAR |
| 2026-05-26 | Scott W Morrison | Director | Grant (A) | +17,084 opt | — | EDGAR | |
| 2026-05-26 | Beth C Seidenberg | Director | Grant (A) | +17,084 opt | — | EDGAR | |
| 2026-05-26 | Patrick G Enright | Director | Grant (A) | +17,084 opt | — | EDGAR | |
| 2026-05-26 | James R Meyers | Director | Grant (A) | +17,084 opt | — | EDGAR | |
| 2026-05-26 | Christy J. Oliger | Director | Grant (A) | +17,084 opt | — | EDGAR | |
| 2026-05-26 | Michael Morrissey | Director | Grant (A) | +17,084 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VERA Insider Holdings
14 insiders · @ $30.78
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Maha Katabi | Director | 7,062,846 | $217.39M | -$15.10M | 10 | 2025-05-16 |
| 2 | Patrick G Enright | Director | 3,602,475 | $110.88M | $32.53M | 11 | 2026-05-26 |
| 3 | Marshall Fordyce | PRESIDENT AND CEO | 376,693 | $11.59M | -$23.74M | 40 | 2026-09-17 |
| 4 | Beth C Seidenberg | Director | 135,565 | $4.17M | $2.90M | 21 | 2026-05-26 |
| 5 | Sean Grant | CHIEF FINANCIAL OFFICER | 119,181 | $3.67M | -$4.55M | 14 | 2026-02-25 |
| 6 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | 80,754 | $2.49M | -$2.02M | 16 | 2026-09-14 |
| 7 | Laurence Matthew Skelton | Chief Commercial Officer | 64,218 | $1.98M | -$66.4K | 2 | 2026-02-25 |
| 8 | Robert Brenner | Chief Medical Officer | 50,947 | $1.57M | -$90.3K | 4 | 2026-02-25 |
| 9 | Jason S Carter | Chief Legal Officer | 49,136 | $1.51M | -$107.5K | 2 | 2025-11-25 |
| 10 | David Lee Johnson | Chief Operating Officer | 45,727 | $1.41M | -$108.3K | 4 | 2026-02-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VERA Board & Officers
As of SEC filings through Sep 17, 2026Directors 11
- Andrew Cheng · since May 13, 2021
- Beth C Seidenberg · since May 13, 2021
- Maha Katabi · since May 13, 2021
- Marshall Fordyce · since May 13, 2021
- Patrick G Enright · since May 13, 2021
- Scott W Morrison · since May 13, 2021
- Kimball Hall · since Dec 10, 2021
- Michael Morrissey · since May 24, 2022
- Christy J. Oliger · since Jun 7, 2024
- James R Meyers · since Nov 25, 2025
- Christopher Hite · since Mar 5, 2026
Officers 9
- Marshall Fordyce · President and CEO · since May 13, 2021
- Sean Grant · Chief Financial Officer · since Jul 12, 2021
- David Lee Johnson · Chief Operating Officer · since Jul 1, 2024
- Joseph R Young · SVP, Finance, Chief Acct Offcr · since May 13, 2021
- Robert Brenner · Chief Medical Officer · since Jan 3, 2024
- William D. Turner · Chief Regulatory Officer · listed since Dec 2025
- Laurence Matthew Skelton · Chief Commercial Officer · since Jan 20, 2026
- Jane Wright-Mitchell · Chief Legal Officer · since Mar 23, 2026
- Nancy Lee Boman · Chief Regulatory Officer · since Aug 3, 2026
Changes in the last 10 years (59)
| Aug 3, 2026 | Nancy Lee Boman became Chief Regulatory Officer |
| Mar 23, 2026 | Jane Wright-Mitchell became Chief Legal Officer |
| Mar 5, 2026 | Christopher Hite became a director |
| Jan 20, 2026 | Laurence Matthew Skelton became Chief Commercial Officer |
| Dec 16, 2025 | The company announced the departure of Jason S Carter as Chief Legal Officer in an SEC filing |
| Dec 4, 2025 | William D. Turner listed as Chief Regulatory Officer (previously Chief Development Officer) in SEC filings |
| Nov 25, 2025 | James R Meyers became a director |
| Nov 18, 2024 | Jason S Carter became Chief Legal Officer |
| Jul 1, 2024 | David Lee Johnson became Chief Operating Officer |
| Jun 7, 2024 | Christy J. Oliger became a director |
| May 17, 2024 | Patrick G Enright no longer listed as a 10% owner in SEC filings |
| Jan 12, 2024 | Commodore Capital LP reported in an SEC filing no longer being a 10% owner |
| Jan 8, 2024 | The company announced the departure of Celia Lin as Chief Medical Officer in an SEC filing |
| Jan 5, 2024 | William D. Turner became Chief Development Officer |
| Jan 3, 2024 | Robert Brenner became Chief Medical Officer |
| Jun 14, 2023 | Commodore Capital LP became a 10% owner |
| May 12, 2023 | Maha Katabi no longer listed as a 10% owner in SEC filings |
| Feb 8, 2023 | Sofinnova Management X-A, L.L.C. first on file as a 10% owner |
| Feb 6, 2023 | Longitude Prime Partners, LLC became a 10% owner |
| Feb 6, 2023 | Longitude Prime Fund, L.P. became a 10% owner |
| Aug 19, 2022 | Abingworth Bioventures 8 LP first on file as a 10% owner |
| Aug 1, 2022 | TC Group, LLC became a 10% owner |
| Aug 1, 2022 | Carlyle Investment Management LLC became a 10% owner |
| Aug 1, 2022 | Carlyle Holdings I L.P. became a 10% owner |
| Aug 1, 2022 | Carlyle Holdings I GP Sub L.L.C. became a 10% owner |
| Aug 1, 2022 | Carlyle Holdings I GP Inc. became a 10% owner |
| Aug 1, 2022 | Carlyle Group Inc. became a 10% owner |
| Aug 1, 2022 | Carlyle Genesis UK LLC became a 10% owner |
| Aug 1, 2022 | CG Subsidiary Holdings L.L.C. became a 10% owner |
| May 24, 2022 | Michael Morrissey became a director |
| Apr 7, 2022 | The company announced the departure of Kurt Von Emster from the board in an SEC filing |
| Dec 10, 2021 | Kimball Hall became a director |
| Jul 12, 2021 | Sean Grant became Chief Financial Officer |
| May 13, 2021 | Sofinnova Venture Partners X, L.P. became a 10% owner |
| May 13, 2021 | Sofinnova Management X, L.P. became a 10% owner |
| May 13, 2021 | Scott W Morrison became a director |
| May 13, 2021 | Patrick G Enright became a director |
| May 13, 2021 | Patrick G Enright became a 10% owner |
| May 13, 2021 | Michael Powell became a 10% owner |
| May 13, 2021 | Merck Serono S.a. became a 10% owner |
| May 13, 2021 | Marshall Fordyce became a director |
| May 13, 2021 | Marshall Fordyce became President and CEO |
| May 13, 2021 | Maha Katabi became a director |
| May 13, 2021 | Maha Katabi became a 10% owner |
| May 13, 2021 | Longitude Venture Partners IV, L.P. became a 10% owner |
| May 13, 2021 | Longitude Capital Partners IV, LLC became a 10% owner |
| May 13, 2021 | Kurt Von Emster became a director |
| May 13, 2021 | Kurt Von Emster became a 10% owner |
| May 13, 2021 | KGaA Merck became a 10% owner |
| May 13, 2021 | Joseph R Young became SVP, Finance, Chief Acct Offcr |
| May 13, 2021 | Jonathan Wolter became Chief Financial Officer |
| May 13, 2021 | Joanne Curley became Chief Development Officer |
| May 13, 2021 | James Healy became a 10% owner |
| May 13, 2021 | Celia Lin became Chief Medical Officer |
| May 13, 2021 | Beth C Seidenberg became a director |
| May 13, 2021 | Bakker Juliet Tammenoms became a 10% owner |
| May 13, 2021 | Ares Trading S.A. became a 10% owner |
| May 13, 2021 | Andrew Cheng became a director |
| May 13, 2021 | Abingworth LLP became a 10% owner |
Not reported recently (26)
- Joanne Curley · Last reported as Chief Development Officer in an SEC filing dated Aug 23, 2023
- Sofinnova Venture Partners X, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Sofinnova Management X, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- James Healy · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Longitude Venture Partners IV, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Longitude Capital Partners IV, LLC · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Bakker Juliet Tammenoms · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Longitude Prime Partners, LLC · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Longitude Prime Fund, L.P. · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Sofinnova Management X-A, L.L.C. · Last reported as a 10% owner in an SEC filing dated Feb 8, 2023
- Abingworth LLP · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Carlyle Holdings I GP Sub L.L.C. · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Carlyle Investment Management LLC · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Carlyle Holdings I GP Inc. · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Carlyle Holdings I L.P. · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Carlyle Group Inc. · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- CG Subsidiary Holdings L.L.C. · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- TC Group, LLC · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Carlyle Genesis UK LLC · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Abingworth Bioventures 8 LP · Last reported as a 10% owner in an SEC filing dated Aug 19, 2022
- Michael Powell · Last reported as a 10% owner in an SEC filing dated May 18, 2021
- Kurt Von Emster · Last reported as a 10% owner in an SEC filing dated May 17, 2021
- Ares Trading S.A. · Last reported as a 10% owner in an SEC filing dated May 14, 2021
- Merck Serono S.a. · Last reported as a 10% owner in an SEC filing dated May 14, 2021
- KGaA Merck · Last reported as a 10% owner in an SEC filing dated May 14, 2021
- Jonathan Wolter · Last reported as Chief Financial Officer in an SEC filing dated May 13, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VERA Proposed Insider Sales (Form 144)
Latest: 2026-06-23
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-23 | MARSHALL FORDYCE | Director, Officer | 74,000 | $2.84M | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-12 | MARSHALL FORDYCE | Director, Officer | 18,500 | $677.3K | 2026-05-12 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-14 | MARSHALL FORDYCE | Director, Officer | 22,951 | $1.00M | 2026-04-14 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-02-23 | LAURENCE SKELTON | Officer | 1,800 | $75.7K | 2026-02-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-23 | WILLIAM DONALD TURNER | Officer | 2,600 | $109.3K | 2026-02-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-23 | SEAN GRANT | Officer | 5,700 | $239.6K | 2026-02-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-23 | ROBERT BRENNER | Officer | 2,500 | $105.1K | 2026-02-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-23 | DAVID L JOHNSON | Officer | 2,900 | $121.9K | 2026-02-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-02-23 | MARSHALL FORDYCE | Officer | 16,600 | $697.8K | 2026-02-23 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-12-15 | WILLIAM TURNER | Officer | 10,000 | $498.0K | 2025-12-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
55 ETFs hold VERA
25 shown · $294.04M total exposure · 0.07% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $62.9M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.57% | $57.2M | $10.0B | 2026-11-05 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.07% | $49.3M | $76.6B | 2026-11-06 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $22.7M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.13% | $17.9M | $13.7B | 2026-11-06 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.12% | $13.2M | $11.1B | 2026-11-06 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.07% | $12.0M | — | 2026-09-30 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $10.7M | — | 2026-08-31 |
| 9 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.03% | $8.5M | — | 2026-11-05 |
| 10 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.10% | $6.4M | $6.6B | 2026-11-05 |
| 11 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.07% | $5.2M | — | 2026-11-05 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.3M | — | 2026-09-30 |
| 13 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.13% | $3.5M | — | 2026-06-30 |
| 14 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.26% | $3.0M | — | 2026-08-31 |
| 15 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $2.8M | $93.2B | 2026-11-06 |
| 16 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.13% | $2.2M | — | 2026-09-30 |
| 17 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.40% | $2.1M | — | 2026-11-06 |
| 18 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.05% | $2.0M | $4.2B | 2026-11-06 |
| 19 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $1.8M | — | 2026-11-05 |
| 20 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $1.5M | — | 2026-11-05 |
| 21 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $1.3M | — | 2026-08-31 |
| 22 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.05% | $1.3M | $2.7B | 2026-11-06 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.07% | $909,396 | — | 2026-11-06 |
| 24 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.02% | $668,053 | $4.0B | 2026-11-05 |
| 25 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $581,220 | $10.0B | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-5.86
TTM Revenue
—
TTM Net Income
$-403.08M
TTM Op. Cash Flow
$-338.65M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-109.72M | $-1.52 | $-100.25M |
| Q1 '26 | 2026-03-31 | — | $-121.97M | $-1.69 | $-106.50M |
| Q4 '25 | 2025-12-31 | — | $-91.10M | $-1.39 | $-69.99M |
| Q3 '25 | 2025-09-30 | — | $-80.29M | $-1.26 | $-61.91M |
| Q2 '25 | 2025-06-30 | — | $-76.66M | $-1.20 | $-54.80M |
| Q1 '25 | 2025-03-31 | — | $-51.43M | $-0.81 | $-54.41M |
| Q4 '24 | 2024-12-31 | — | $-43.42M | $-0.72 | $-39.18M |
| Q3 '24 | 2024-09-30 | — | $-46.63M | $-0.85 | $-36.88M |
| Q2 '24 | 2024-06-30 | — | $-33.71M | $-0.62 | $-24.78M |
| Q1 '24 | 2024-03-31 | — | $-28.38M | $-0.56 | $-33.83M |
| Q4 '23 | 2023-12-31 | — | $-25.66M | $-0.58 | $-25.14M |
| Q3 '23 | 2023-09-30 | — | $-20.10M | $-0.45 | $-22.97M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
5.15
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-98.9%
ROA
-75.6%
Div Yield
0.00%
FCF Yield
-16.14%
Debt/Equity
0.18
Current Ratio
—
Market Cap
$2.10B
as of 2026-11-09
VERA vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. Common Stock | $10.2B | — | — | +78.2% | — |
| CRNX Crinetics Pharmaceuticals, Inc. | $9.0B | — | +2928.4% | +81.8% | — |
| ORKA Oruka Therapeutics, Inc. Common Stock | $6.8B | — | — | +272.3% | 5 |
| CGON CG Oncology, Inc. Common stock | $6.7B | — | +666.0% | +77.9% | 100 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | $4.8B | — | −60.8% | +128.8% | 76 |
| TVTX Travere Therapeutics, Inc. Common Stock | $4.8B | — | +49.4% | +28.9% | 21 |
| XENE Xenon Pharmaceuticals Inc | $3.8B | — | — | −9.4% | 52 |
| DYN Dyne Therapeutics, Inc. Common Stock | $3.4B | — | — | +1.5% | 86 |
| VERA Vera Therapeutics, Inc. Class A Common S | $2.1B | — | — | −36.7% | 36 |
| Peer median | $5.8B | — | +357.7% | +78.1% | 64 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
13.59M
SI % of Float
21.49%
Days to Cover
7.17
Short Vol Ratio
44.2%
Free Float
63.21M
Float %
87.7%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14